Cardio-renal-metabolic (CaReMe) conditions are common and the leading cause of mortality around the world. Genome-wide association studies have shown that these diseases are polygenic and share many genetic risk factors. Identifying individuals at high genetic risk will allow us to target prevention and treatment strategies. Polygenic risk scores (PRS) are aggregate weighted counts that can demonstrate an individual's genetic liability for disease. However, current PRS are often based on European ancestry individuals, limiting the implementation of precision medicine efforts in diverse populations. In this study, we develop PRS for six diseases and traits related to cardio-renal-metabolic disease in the Penn Medicine Biobank. We investigate their performance in both European and African ancestry individuals, and identify genetic and phenotypic overlap within these conditions. We find that genetic risk is associated with the primary phenotype in both ancestries, but this does not translate into a model of predictive value in African ancestry individuals. We conclude that future research should prioritize genetic studies in diverse ancestries in order to address this disparity.
Introduction
In this era of precision medicine, there are significant efforts to identify the genetic, environmental, family history, and clinical factors that influence the risk of disease as well as the influence of these factors on disease prognosis and treatment. Knowing in advance the factors that can lead to increased risk of disease can provide a major health benefit to individuals, as treatment and support strategies can be targeted towards individuals at higher risk. Identification of a large number of loci with small genetic effects in genome-wide association studies (GWAS) have highlighted the polygenic behavior of most common, complex diseases 1, 2 . An emerging technology in the field of disease risk prediction is the polygenic risk score (PRS). PRS is the cumulative, mathematical aggregation of risk derived from the contributions of many DNA variants across the genome 3 . suffers from this same phenomenon 17 . In this study, we investigated the implementation of PRS for cardio-renal-metabolic conditions in European (EUR) and African (AFR) ancestry individuals in the Penn Medicine Biobank (PMBB). PMBB is a cohort of 52,853 individuals established for genomic and precision medicine research. Approximately 20,000 of the individuals in the study have genetic data from a genotyping array which has been imputed to the 1000Genomes phase III using the Michigan Imputation Server 18 . Approximately 25% of the PMBB study population is African ancestry. We calculated PRS in the PMBB genetic data to evaluate 1) risk prediction accuracy among EUR and AFR based on GWAS summary statistics generated in EUR data; and 2) the utility of PRS in determining genetic overlap among CaReMe conditions.
Methods

Penn Medicine Biobank
The Penn Medicine BioBank (PMBB) recruits participants through the University of Pennsylvania Health System by enrolling at the time of appointment. Patients participate by donating either blood or a tissue sample and allowing researchers access to their electronic health record (EHR) information. This academic biobank provides researchers with centralized access to a large number of blood and tissue samples with attached health information. The facility banks both blood specimens (i.e., whole blood, plasma, serum, buffy coat, and DNA isolated from leukocytes) and tissues (i.e., formalin-fixed paraffin-embedded, fresh and flash frozen).
PMBB currently consists of 52,853 consented samples. Approximately one third (N=19,515) of these participants have been genotyped to date. PMBB is a diverse cohort, with 70% European ancestry, 25% African ancestry, and 5% Asian or Latino ancestry. See Table 1 for characteristics of all participants. strategy to combine these datasets 18, 19 . Prior to imputation, we applied a quality control pipeline 19 to each dataset, removing individuals with sex errors or had a sample call rate <90%;
and removing variants which were palindromic or had a call rate <95%. Table 2 summarizes each dataset before and after QC. principal components were generated within each ancestral group following ancestry assignment, and these were used as covariates for subsequent analyses. Genetic ancestry of individuals was determined by performing quantitative discriminate analyses on PCs.
Polygenic Risk Scores
To derive PRS, we used the summary statistics from the largest and/or most recent GWAS studies for each trait (See Table 3 
Phenotypes
We derived phenotypes using ICD-9 and ICD-10 data for 52,853 individuals from the electronic health record (EHR), consisting of 11.8 million records. We filtered on encounter type to identify records representing encounters with a physician (see Supplemental Table 1 for encounters selected). ICD-9 codes were aggregated to phecodes using the phecode ICD9 map 1.2 10, 23 ; ICD-10 codes were aggregated to phecodes using the phecode ICD-10cm map 1.2 (beta) 24 . Individuals are considered cases for the phenotype if they have at least 2 instances of the phecode on unique dates, controls if they have no instance of the phecode, and 'other/missing' if they have one instance or a related phecode. By the following criteria, there were a total of 1,812 phecodes included in the analysis.
Statistical Analysis
PRS were standardized with mean = 0 and SD = 1. Logistic regression models accounting for age, sex, and the first 10 within-ancestry principal components (PCs) were used to test for association of PRS with the primary phenotype. Area under the receiver operator curve (AUC) was determined using the R package pROC, using the same logistic regression model as above.
AUC was also calculated for covariates alone.
A Phenome-wide Association Study (PheWAS) was performed for the optimal PRS identified in the above analysis for each primary condition. Logistic regression models with each PRS as the independent variable, phecodes as the dependent variables, and age, sex, and the first 10 PCs as covariates were used to identify secondary phenotypic associations. A phenome-wide bonferroni significance threshold of 2.7 × 10 -5 was applied to account for multiple testing.
Results
Demographics of PMBB dataset
Using phecodes, we identified 7,476 EUR ancestry individuals (73.4%) and 4,177 AFR ancestry individuals (76.4%) with either type 2 diabetes, obesity, hypertension, myocardial infarction, coronary atherosclerosis, or renal failure (Table 4 ). In EUR ancestry individuals, 24 .7% had been diagnosed with one instance of disease, 35.2% had 2-3 diseases, 12.5% had 4-5 diseases, and 1.0% had all six diseases. In AFR ancestry individuals, 20.8% had been diagnosed with one instance of disease, 39.1% had 2-3 diseases, 14.6% had 4-5 diseases, and 1.9% had all six diseases. 
Determining the PRS with the best discriminative capacity
We generated a PRS for each phenotype of interest: type 2 diabetes, body mass index, hypertension, myocardial infarction, coronary artery disease, and chronic kidney disease (see methods, Table 3 ). Candidate PRS were generated for 7 parameters, and their association with the primary phenotype tested. All PRS had at least one parameter that was significantly associated with their primary phenotype (Figure 1 , Supplemental Table 2 ). We selected the best performing PRS based on the maximum area under the receiver operator curve (AUC;
Supplemental 
Performance of PRS in EUR vs. AFR ancestry
We selected the parameter that produced the strongest associated candidate PRS for each PRS-phenotype grouping within each ancestry for further analysis. In all cases, PRS performance was best in European ancestry individuals. The distribution of PRS in cases and controls in both populations is illustrated in Figure 2 . In European ancestry, the mean distribution of PRS in cases is consistently higher than controls. In African ancestry individuals this difference is much smaller, with substantial overlap between the PRS distribution in cases and controls. This is reflected in the comparison between the AUC for the full model and the AUC for covariates alone (Supplemental Table 3 Table 4 ). 
Correlation of PRS
We next tested for correlations between the polygenic risk scores for the six selected diseases in each ancestry (Figure 3 , Supplemental Table 5 ). In European ancestry individuals, we 
Association of PRS with disease burden in cases
Using linear regression in cases only, we tested whether increased PRS is associated with increased burden of cardio-renal-metabolic disease. All PRS, except for CKD PRS, were significantly associated with increased disease burden in both European and African ancestry individuals ( Table 5 ). In Europeans, BMI PRS was the strongest association with occurrence of S th multiple diseases (beta=0.14, p=6.6x10 -19 ) , in contrast to in African ancestry individuals, where the association remained significant but was reduced in effect size (beta=0.05, p=0.02). In African ancestry individuals, MI PRS was the strongest association with increased disease burden (beta=0.09, p=8.3x10 -7 ). 
PheWAS of polygenic risk scores reveals secondary associations
We performed a PheWAS of each PRS in both European and African ancestry individuals to identify secondary phenotypes associated with genetic risk (Figure 4 , Supplemental Tables 6-11 ). In all PRS, associations with secondary phenotypes in AFR individuals were reduced. All PRS except CKD PRS were associated with secondary phenotypes. T2D PRS was associated with hypertension (OR=1. 13 
Discussion
We generated six polygenic risk scores representing genetic liability for cardio-renalmetabolic diseases, and investigated their performance in both European and African ancestry individuals in the Penn Medicine BioBank (PMBB), a biobank linked with electronic health records. For all phenotypes tested, we identified a significant association between the PRS and the primary phenotype in both ancestry groups. However, the ability of the PRS to discriminate between cases and controls varied among phenotypes. Furthermore, none of the PRS in AFR were sufficient to stratify individuals according to risk.
In European ancestry individuals, the PRS with the largest effect size was myocardial infarction, followed by coronary artery disease. The two GWAS that were used to generate these PRS also had the largest number of cases, and the PMBB dataset also contained a large number of cases for both of these diseases. However, the CKD PRS was the weakest performer in terms of effect size, despite it being based on the next largest GWAS and the PMBB containing a large number of individuals with renal failure. Therefore, while case number in both the GWAS and the target sample are clearly important, we believe that other factors such as disease heterogeneity, prevalence, penetrance, and non-additive effects among others must also play a role in the ability of PRS to associate with disease.
We conducted a number of analyses to explore secondary phenotypes associated with each PRS. First, we show that the PRS generated for the six diseases are correlated with each other, a finding supported by prior studies showing genetic correlations between CaReMe conditions 4 . We next show that increased PRS is associated with increased burden of disease, suggesting that a higher PRS burden may contribute in a non-discriminating fashion to disease outcome. Finally, we perform PheWAS analysis to identify secondary phenotypes associated with genetic liability for CaReMe diseases. Many of the secondary phenotypes identified could be attributed to the broader effects of disease risk factors and known comorbidities. For instance, risk for Type 2 diabetes was associated with hypertension, a known commonly co-occurring trait 25 . The BMI PRS was associated with sleep apnea, diabetes, hypertension and osteoporosis;
all traits known to increase in individuals with higher BMI [26] [27] [28] [29] . The extent to which these secondary phenotypes reflect causal associations between genetic risk and disease is unclear due to the commonality of co-morbidity of these traits.
Our findings highlight a major issue in the future implementation of PRS in clinical care.
While GWAS conducted in EUR populations can be used to generate PRS that are associated with phenotype in AFR individuals, the scores generated are not sufficient to differentiate between cases and controls in a predictive model. This was an expected finding, and has been discussed widely in recent years as being a critical source of disparity in genetic research 14, 16 .
Due to differences in linkage disequilibrium patterns, effect sizes, and causal variants themselves, conducting GWAS in populations that are reflective of the patient population are necessary and will need to be prioritized in the coming years.
Finally, while there is much excitement and enthusiasm about PRS for clinical care, there is still significant research to be conducted to determine its optimal implementation. One of the most essential needs is to investigate how PRS can be incorporated alongside information commonly used to predict patients' risk, such as family history, clinical comorbidities, and environmental/lifestyle factors. Many chronic diseases have published clinical guidelines with risk reduction recommendations (for example CVD 30 ). The ultimate clinical utility of PRS will come to fruition when we understand how to integrate PRS with these published guidelines.
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